Baudax Bio stops Anjeso sales, evaluating monetization approaches

Baudax Bio disclosed late Friday that the discontinuation of sale of Anjeso was acknowledged by FDA via listing in the Orange Book. Baudax Bio said it continues to evaluate alternative approaches to the monetization of Anjeso both in the United States and outside the United States. It added, "The Company believes that, assuming that target product profiles are met in clinical development, the combined NMB and reversal agent products represent an opportunity to further improve patient management and time and cost efficiency for surgical cases where NMB usage is appropriate. BX 1000, an intermediate acting NMB, is currently enrolling patients to a phase 2 clinical trial in abdominal surgical conditions with a preplanned first interim analysis expected early in 2023, and with a goal to complete enrollment in the full study by the end of the first quarter of 2023. BX 2000, an ultrashort acting NMB, is in a dose escalation study in healthy volunteers which the Company plans to complete in 2023. BX 3000 is a proprietary reversal agent which chemically breaks the BX 1000 and BX 2000 molecules and inactivates them. Baudax is conducting preclinical studies for BX 3000 to support an IND filing anticipated for the summer of 2023."